Companies › Molecular Partners
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [212Pb]Pb-MP0712 DLL3-targeting radioligand therapy (alpha particle emitter) | DLL3 | Phase 1 | Large Cell Neuroendocrine Carcinoma | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07278479 | [212Pb]Pb-MP0712 | Phase 1 | Large Cell Neuroendocrine Carcinoma | Oncology | Sep 2028 |
Cash of 83m CHF on 2025-12-31; operating cash outflow about 51m CHF a year; runway about 19 months at that burn, to Aug 2027
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.